ORMP (Oramed) יחס שווי שוק לשווי בספרים

The current price chart for Oramed Pharmaceuticals (ORMP) reflects the dynamics of a company developing an oral protein delivery system with strict temperature control, which sustains high profits at the level of 0.53. The business minimizes research risks by creating tablets instead of injections for the diabetes market. A stable image as an innovator in the eyes of major funds confirms the brand's long-term reliability.

This indicator compares the total market value of Oramed Pharmaceuticals (ORMP) with its total equity. The calculation determines the multiple of the market price to net assets, identifying the degree of stock overvaluation. By analyzing the market capitalization to book value ratio, an investor can see the gap between real resources and market expectations. For Oramed Pharmaceuticals (ORMP), this discrepancy is driven by speculation surrounding the development of oral insulin. The volatility of the line reflects regulatory confidence in the drug's success rather than the current value of assets.